Halozyme Therapeutics, Inc. Stock News
$45.65
15.40%
yesterday
Nasdaq,
Nov 15, 10:00 pm CET
Halozyme Therapeutics, Inc. Stock News
AD HOC NEWS
●
one day ago
SAN DIEGO/HAMBURG - Die US-Biotechfirma Halozyme Therapeutics US40637H1095 will den deutschen Wirkstoffentwickler Evotec DE0005664809 kaufen.
AD HOC NEWS
●
one day ago
Die US-Biotechfirma Halozyme Therapeutics US40637H1095 will den deutschen Wirkstoffentwickler Evotec DE0005664809 kaufen.
Neutral
PRNewsWire
●
one day ago
Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ: EVO...
Positive
Reuters
●
one day ago
German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.
AD HOC NEWS
●
2 days ago
Die US-Biotechfirma Halozyme Therapeutics US40637H1095 will den Wirkstoffentwickler Evotec DE0005664809 kaufen.
AD HOC NEWS
●
2 days ago
SAN DIEGO/HAMBURG - Die US-Biotechfirma Halozyme Therapeutics US40637H1095 will den Wirkstoffentwickler Evotec DE0005664809 kaufen.
Negative
Seeking Alpha
●
10 days ago
Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong partnerships with J&J and Roche. The partnership model using ENHANZE tech mitigates risks, enhances operational efficiency, and offers partners a way to avoid patent cliffs, ensuring long-term growth. Despite strong near-term growth prospects, potential patent disputes an...
Positive
FXEmpire
●
15 days ago
Halozyme Therapeutics, Inc. (HALO) shares are up after record revenue growth, improved guidance, and expansion plans.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
